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Summary The structure of circulating chromogranin A (CgA) of phaeochromocytoma patients was
characterised and compared with that of CgA extracted from tumours. Size exclusion chromatography
experiments provided evidence that CgA is present in the blood of different patients, as well as in tumour
extracts, as multiple forms having different hydrodynamic sizes of 600 kDa (CgA-I), 100 kDa (CgA-II) and
55 kDA (CgA-III). The amount ofeach CgA form as a proportion of the total antigenic material was different
in different patients. Western blot analysis ofchromatographic fractions indicated that these fonns are made up
by polypeptides of similar molecular weight (about 60-70 kDa). All CgA forms express the epitopes
recognised by two monoclonal antibodies (All and B4El 1), directed against residues 68 -70 and 81 -90 of
human CgA. However, their relative immunoreactivity was markedly different. No evidence for the presence of
multimeric complexes in the CgA-I fraction was obtained by various immunological and biochemical methods.
These results suggest that circulating CgA in phaeochromocytoma patients consists of at least three forms that
appear to be made up by polypeptides with similar molecular weight and different hydrodynamic properties
and immunoreactivity. We hypothesise that different conformations and shapes contribute to the heterogeneity
of circulating CgA.
Keywords: chromogranin; endrocine/neuroendocrine tumours; tumour marker; monoclonal antibody; size
exclusion chromatography
Chromogranins A (CgA) and B (CgB) are acidic proteins
contained in the secretory granules of many endocrine and
neuroendocrine cells and secreted with the co-resident
hormones (Winkler and Fisher-Colbrie, 1992). cDNA
sequence analysis and biochemical studies have shown that
CgA and CgB are hydrophilic proteins, 439 and 657 residues
long, respectively, with a high proportion of acidic amino
acids (Benedum et al., 1987; Konecki et al., 1987; Helman et
al., 1988; Wu et al., 1991). Both proteins are characterised by
several post-translational modifications including glycosyla-
tion, sulphation and phosphorylation (Simon and Aunis,
1989; Winkler and Fisher-Colbrie, 1992). Although the
specific intracellular and extracellular function of CgA is
not yet clearly understood, it is thought that this protein is a
multivalent precursor of several polypeptides that may exert
intracrine, autocrine, paracrine and endocrine effects (Helle
and Angeletti, 1994). Accordingly, CgA contains a high
number of dibasic sites thought to be important for
proteolytic processing and biological activity (Metz-Boutigue
et al., 1993).
CgA has been recognised as a useful tissue marker for a
variety of endocrine cells (Deftos et al., 1988; Weiler et al.,
1987; Totsch et al., 1992; Rosa and Gerdes, 1994). Moreover,
since increased levels of CgA have been found in the blood of
some patients with endocrine and neuroendocrine tumours
(O'Connor and Bernstein, 1984; Sobol et al., 1986; Hsiao et
al., 1990; Deftos, 1991; Johnson et al., 1993), detection of
CgA antigen in serum could be of great clinical and
experimental interest.
In this work we have characterised the structure of
circulating CgA forms in phaeochromocytoma patients, using
chromatographic, electrophoretic and immunochemical tech-
niques.
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We provide evidence to suggest that CgA is present in the
blood of different patients and in tissues under different
forms with markedly different hydrodynamic properties and
immunoreactivity, made up by polypeptides of similar
molecular weight.
Materials and methods
Materials
Becton Dickinson (Oxnard, CA, USA) supplied 96-well
polyvinyl chloride (PVC) microtitre plates (Falcon Micro
Test III flexible assay plates). Bovine serum albumin (BSA,
fraction V), polyoxyethylene sorbitan monolaurate (Tween
20), goat anti-mouse IgG horseradish peroxidase conjugate
(GAM-HRP), goat anti-rabbit IgG-HRP conjugate
(GAR-HRP), normal mouse serum (NMS), normal goat
serum (NGS), o-phenylenediamine dihydrochloride (OPD)
and streptavidin-HRP (STV-HRP) were from Sigma
Chemical (St. Louis, MO, USA). D-Biotinyl-6-aminocaproic
acid N-hydroxysuccinimide ester was from Societa Prodotti
Antibiotici (Milan, Italy). Enhanced chemiluminescence
(ECL) Western blotting kit was from Amersham Italia SRL
(Milan, Italy). Milk 'Humana 3' was from Humana Italia
(Milan, Italy). CHP-134 neuroblastoma cells were obtained
from Dr G Della Valle (University of Pavia, Italy). CHP-134
cell supernatants were harvested from confluent CHP-134
cells, cultured in RPMI, 20% fetal calf serum (FCS), 2 mM
glutamine, 100 U ml-' penicillin, 100 jug ml-' streptomycin,
25 jug ml-' amphotericin B, at 37°C, 5% carbon dioxide.
Phaeochromocytoma and VIPoma heat-stable fractions
(HSFs) were prepared as follows: tissues were frozen in liquid
nitrogen immediately after surgical excision, lyophilised and
homogenised in distilled water. The homogenate was boiled
for 6 min and centrifuged at 120 000 g for 30 min. The
supernatants containing CgA and CgB, which are heat stable
(Rosa and Gerdes, 1994), were kept at -20°C until use.
Protein concentration was measured using the 'BioRad
Protein Assay' kit.
Peripheral blood from healthy controls (n =22) was
anticoagulated with EDTA (5 mM) or sodium citrate
(129 mM), kept in ice and centrifuged at 900 g at 4'C for
20 min. Serum samples were also prepared from the blood ofCharacterisation of circulating chromogranin A
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the same subjects (n =22). Preoperative (n =7) and post-
operative (n =2) sera were obtained from patients with
documented phaeochromocytoma. All plasma and serum
samples were stored at -20°C.
Anti-chromogranin antibodies
Monoclonal antibody (MAb) Al (anti-CgA) and MAb Bi 1
(anti-CgB) were prepared from one mouse immunised with
phaeochromocytoma heat-stable fractions (HSFs) (Pelagi et
al., 1989). MAb B4E11 was prepared as follows: one BALB/c
mouse was immunised by injecting, intraperitonally (i.p.),
50 Sg of VIPoma HSF emulsified 1:1 with complete
Freund's adjuvant. At 15 day intervals the animal was
boosted by injecting 50 ,g of VIPoma HSF, i.p. in
incomplete Freund's adjuvant (one boost) and in phos-
phate-buffered saline solution (PBS) (0.15 M sodium chloride,
0.05 M sodium phosphate buffer, pH 7.3) (four boosts). Three
days after the last boost, the mouse was sacrificed. Spleen
cells were isolated and fused with P3-X63 Ag8-NSI myeloma
cells to generate hybridomas, according to standard
procedures (Galfre and Milstein, 1981).
Hybridomas secreting anti-chromogranin A antibodies
were screened by ELISA as described (Pelagi et al., 1989).
One clone, named B4E11, was selected for further character-
isation and use.
Anti-phaeochromocytoma HSF IgGs were obtained from
the sera of two mice immunised with phaeochromocytoma
HSF as described (Pelagi et al., 1989). The serum pool
(1.1 ml) was diluted 1: 5 with 1.5 M glycine, 4 M sodium
chloride, pH 9.0 and loaded on a Protein A-Sepharose
column pre-equilibrated with the same buffer. After washing,
bound IgGs were desorbed with 0.1 M sodium citrate pH 3.0,
neutralised and precipitated with 313 mg ml-1 ammonium
sulphate. The product (327 Mg protein) was dialysed against
water and stored at -200C.
Monoclonal and polyclonal IgGs were biotinylated as
follows: 1 ml and 0.3 ml aliquots, respectively, of 1 mg ml-'
antibody solutions in water were mixed with 1 M sodium
carbonate buffer, pH 8.8 (0.1 M final concentration), and
with a 1 mg ml-' D-biotinyl-6-aminocaproic acid N-hydro-
xysuccinimide ester solution in dimethyl sulphoxide (DMSO)
(0.09 mg ml-1 final concentration). After incubation for 4 h
at room temperature, the solutions were mixed with 1 M
lysine (92 mm final concentration) and further incubated
48 h at 4°C. Each product was dialysed overnight against
0.15 M sodium chloride, 0.05 M sodium phosphate, pH 7.3
(PBS) and stored as stock solution at -20°C.
Purification of CgA and CgB
CgA and CgB were purified from phaeochromocytoma HSF
as follows: two columns bearing MAb Al1 or Bi1 were
prepared by coupling 3 mg of antibody to 1 g of activated
CH-Sepharose (Pharmacia), using 0.1 M sodium carbonate,
pH 8.0, as coupling buffer (1 h at 4°C), and 0.1 M Tris-HCl
as blocking agent (1 h at 4°C). After column washings (three
times with 0.5 M sodium chloride, 0.1 M Tris-HCI buffer,
pH 8.0, and with 0.5 M sodium chloride, 0.1 M sodium
acetate buffer, pH 8.0) phaeochromocytoma HSF, 1 mg in
3 ml of PBS. was loaded onto the MAb Al1-agarose
column and washed with PBS until the absorbance of the
effluent reached the base line. The column was then eluted
with 0.5 M sodium chloride, 0.2 M glycine, pH 2.0. Peak
fractions containing CgA were identified by M-ELISA (see
below). The protein content in the starting material and in
the purified fraction was quantified using the 'BioRad Protein
Assay' kit. About 20% of total protein loaded onto the
column was recovered in the bound fraction. Moreover,
detection of CgA by P-ELISA (see below) showed that more
than 95% of immunoreactivity present in the starting
material was recovered in the bound fraction and less than
1% in the unbound fraction. After pH neutralisation, the
CgA fraction was kept at -20°C. CgB was purified from
phaeochromocytoma HSF, CgA-depleted fraction, using the
B 11-agarose column essentially as described for CgA.
CgA M-ELISA and P-ELISA
CgA was detected using two analytical systems called M-
ELISA and P-ELISA. Schematic representations of CgA M-
ELISA and P-ELISA are shown in Figure 1. PVC microtitre
plates were coated with B4E11 (10 jug ml-' in PBS, 50 Ml per
well, overnight at 4°C). All subsequent steps were carried out
at room temperature. After washing three times with PBS,
the plates were blocked with 3% bovine serum albumin
(BSA) in PBS (200 Ml per well for 2 h) and washed with PBS
again. CgA standard or sample solutions, diluted 1: 2 in
PBTN (PBS containing 0.5% BSA, 0.05% Tween 20, and
2.5% NGS) were added (50 Ml per well) and incubated for
2 h. The plates were washed eight times by emptying and
filling with PBS containing 0.05% (v/v) Tween 20 (PBS-T),
and incubated with biotinylated MAb A1, 2 Mg ml-' (M-
ELISA) or biotinylated mouse anti-phaeochromocytoma
HSF IgGs, 5 jug ml- (P-ELISA), both in PBTN (50 Ml per
well for 1.5 h). The plates were washed again with PBS-T and
further incubated with STV-HRP (1:1000 in PBTN, 50 Ml
per well for 1 h). After the final wash, the plates were
incubated with 0.4 mg ml-' o-phenylenediamine solution in
0.05 M phosphate-citrate buffer (pH 5.0) containing 3.5 mM
hydrogen peroxide (100 Ml per well for 45 min). The reaction
was stopped by adding 10% (v/v) sulphuric acid (100 ,l per
well) and the absorbance of each well was read at 492 nm.
Each assay was calibrated with eight phaeochromocytoma
HSF solutions at various concentrations. The results were
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Figure 1 Calibration curves of CgA M-ELISA and P-ELISA.
Insets: schematic representations of the assays.
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calculated considering that 20% of total protein in this
extract is antigenically related to CgA, as judged from
immunoaffinity purification recovery (see above). Detection
of CgA antigen in this extract by P-ELISA at various
dilutions (1: 4000, 1: 8000, 1:16 000, 1: 32 000), using a
calibration curve set up with purified CgA, was 24.5 +
0.89% of total protein in agreement with previous results.
This also indicates a good parallelism of response between
crude and purified CgA.
Western blot analysis
Sodium dodecylsulphate-polyacrylamide gel electrophoresis
(SDS-PAGE) was carried out in a Phast System apparatus
(Pharmacia) using ready made polyacrylamide gels (Phast
Gels 12.5%, Pharmacia). Samples were two-fold diluted with
20 mM Tris-HCl, pH 8.0, containing 2 mM EDTA, 5%
(w/v) SDS, 10% (v/v) /3-mercaptoethanol, 0.02% (w/v)
bromophenol blue, and boiled for 3 min before electrophor-
esis. Western blot analysis was carried out essentially as
follows: proteins, after SDS-PAGE, were electrophoretically
transferred to nitrocellulose membranes using 20 mA for
25 min, and 25 mM Tris, 150 mM glycine, 20% (v/v)
methanol (pH 8.9) as transfer buffer. The nitrocellulose
membranes were rinsed twice with PBS and were incubated
overnight at 4°C in PBS containing 1% BSA and 3% milk.
The membranes were then incubated for 2 h with anti-CgA
or anti-CgB MAbs (2 ig ml-') in PBS containing 1% BSA,
3% milk, 1% NGS (PBMN). After washing with PBS
containing 0.02% (v/v) Tween 20, the membranes were
further incubated for 2 h with GAM-HRP (1:1000) in
PBMN. After the final wash, the visualisation reaction was
carried out with 'ECL Western Blotting' kit (Amersham),
based on luminol substrate and a chemiluminescent principle.
Size exclusion HPLC
HPLC gel filtration (SE-HPLC) was carried out at room
temperature using a BioSil 250 Guard column joined to a
BioSil SEC-250 column (BioRad) as follows: the column was
equilibrated and eluted with PBS containing 0.5% BSA (flow
rate 0.6 ml min-'). Fractions (0.3 ml) were collected and
stored at -20°C until analysis. The column was calibrated
using thyroglobulin (670 kDa), IgG (158 kDa), bovine serum
albumin (66 kDa), ovalbumin (44 kDa), myoglobin (17 kDa)
and cyanocobalamin (1.3 kDa), as molecular markers.
Stability of CgA forms
To evaluate the stability of CgA forms, aliquots of
phaeochromocytoma plasma samples were thawed, incu-
bated at -20°C, 4°C and 37°C for 72 h and further frozen
at - 20°C. Each aliquot was then thawed, filtered through a
0.45 ,um filter and analysed by SE-HPLC. Each chromato-
graphic fraction was analysed by P-ELISA.
Results
CgA sandwich ELISAs
Monoclonal as well as polyclonal reagents were used to
develop sandwich ELISAs for measuring CgA. In particular,
two sandwich ELISAs for CgA, called CgA M-ELISA and
CgA P-ELISA, were developed. A schematic representation
of each assay is depicted in Figure 1. As shown, CgA M-
ELISA is based on a sandwich reaction between two
monoclonal antibodies (B4Ell and Al1), while the CgA P-
ELISA is based on one monoclonal antibody (B4E11) and
biotinylated mouse anti-phaeochromocytoma HSF polyclonal
IgGs.
To verify the specificity of each assay for CgA, the
reactivity of purified CgA and CgB was analysed. The cross-
reactivity of CgB in the CgA M-ELISA and P-ELISA was
less than 0.1%, indicating that these assays can be reliably
used for measuring CgA even in the presence of CgB.
Detection of CgA antigens in serum and plasma
The CgA content in the serum and plasma of human cancer
patients was first measured by P- and M-ELISA. In
agreement with previous findings (O'Connor and Bernstein,
1984; O'Connor and Deftos, 1986), the results indicate that
CgA levels, as measured by both assays, are increased in
phaeochromocytoma patients in comparison with normal
subjects (Table I). Moreover, CgA levels decreased to normal
values after tumour surgery, suggesting that CgA antigen, as
measured by P- and M-ELISA, could be a useful tumour
marker. However, the ratio between CgA values measured by
M- and P-ELISA ('P/M ratio') was different in different
patients ranging from 0.45 to 2.8. This suggests that the
biological fluids examined contain different antigenic forms
that are differentially recognised by different assays. Of note,
some variability in the P/M ratio was observed, though to a
lower extent, within serum samples from normal subjects
(from 1.5 to 2.12) and plasma samples (from 1.3 to 2.1).
Assay validation studies showed that P-ELISA intra-assay
(n=10) and interassay (n =6) coefficient of variation (CV),
was 5.2% and 22.5%, respectively, as determined using ten
serum samples from normal subjects and patients. Similarly,
M-ELISA intra-assay CV was 6.3%, while interassay CV was
19.5%. To evaluate the parallelism of response between sera
and standards, four serum samples were analysed at 1: 3 and
1:6 dilution. The values obtained by P-ELISA and M-
ELISA at 1: 6 dilution were 96.0 + 3.9% and 121 + 47.8%
Table I Detection of CgA in the serum and plasma of normal subjects and of phaeochromocytoma patients
CgA (ng mrl', mean+s.d.)
Sample M-ELISA P-ELISA P/M
Normal subjects (n =22)
(S) (serum) 24+ 6.4 43.2 +6.4 1.79+0.2
(P) (plasma-citrate) 25+ 8.6 43.4+ 16 1.72+0.2
(P) (plasma-EDTA) 33+ 9.6 50.2+ 28.2 1.49+0.45
Phaeochromocytoma
patients (n=9)
S1 80.4 168.8 2.1
S2 48.2 120 2.5
S3 90.2 45 0.5
S3p 17.6 8 0.45
S4 1866 3108 1.66
S5 32.2 29.8 0.92
S6 20.4 52.8 2.58
S7 19.8 50 2.5
S7p 5 14 2.8
P1 220 560 2.54
P2 110 260 2.36
p, After surgery.(mean+s.d.) respectively, of the values obtained at 1: 3
dilution. Thus, while a good parallelism of response was
observed with P-ELISA, the effect of dilution on the
analytical recovery obtained by M-ELISA was more variable
and dependent on serum samples.
This also suggests that different samples contain forms
with different immunoreactivity with MAb All and B4EIl.
Characterisation of circulating CgA forms
To characterise the molecular forms of circulating CgA and
to investigate the cause for the discrepancies observed with
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different assays, the molecular weight of serum and tissue
CgA was characterised by SE-HPLC.
As shown in Figure 2, the chromatographic behaviour of
CgA present in the serum of different patients was markedly
different. In particular, at least three peaks eluting at
600 kDa (CgA-I), 100 kDa (CgA-II) and 55 kDa (CgA-III)
were observed, in different proportions, within serum samples
from different patients.
Interestingly, the 'P/M ratio' of these sera before
chromatography was different, increasing from 0.5 to 2.5 in
patients with an increasing proportion of CgA-I. Accord-
ingly, the 'P/M ratio' of isolated fractions ranged from about
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Figure 2 SE-HPLC of three phaeochromocytoma serum samples (SI, S2 and S3, lOOgI aliquots), phaeochromocytoma HSF
(100 jil, 20 gml- 1), purified CgA (I0Mgml -, 100 jl) and CHP-134 cell supernatant (100pl). Fractions were analysed by M-ELISA.
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2.5 (CgA-I) to 0.5 (CgA-III), suggesting that CgA-I is
detected more efficiently by P-ELISA, whereas CgA-III is
detected more efficiently by M-ELISA, when compared with
the phaeochromocytoma HFS standard. In conclusion, these
results suggest that the discrepancies observed with different
assays are related to the presence of variable proportions of
three forms of CgA characterised by a different behaviour in
SE-HPLC.
Other biological samples with a higher content of CgA
were then analysed. Interestingly, CgA forms similar to those
found with serum samples were obtained by SE-HPLC of
crude phaeochromocytoma HSF (used as reference standards
in M- and P-ELISA) and immunopurified CgA, while fresh
CHP-134 neuroblastoma cell supernatants contained mainly
the CgA-I form (Figure 2, right panels). Also in these cases,
the proportion of each form over the total was variable.
Moreover, as described above for serum samples, P-ELISA
was more efficient in detecting CgA-I, whereas M-ELISA
detected more efficiently CgA-III fractions (Figure 3).
Peak fractions were then analysed by SDS-PAGE under
non-reducing conditions and Western blotting with MAb
B4E11. As shown in Figure 4, the CgA-I and CgA-II
obtained by SE-HPLC of phaeochromocytoma HSF and of
one serum sample containing 2-3 jMg ml-' CgA (sample S4)
400
200
0
were resolved in two main bands of 60-70 kDa (lanes b,d
and g). Similarly, the CgA-III was resolved in a main band of
about 60 kDa (lanes c and f). Thus, the distinct forms
observed by SE-HPLC appear to be made up by
polypeptides with a very similar molecular weight. Of note,
some bands of lower relative mass probably corresponding to
proteolytic fragments, were observed with CgA-I and CgA-II
from phaeochromocytoma HSF (lanes b and d) but not with
serum or CHP-134 CgA-I (lanes g and h). We do not know
the reason for this behaviour. However, one band of
approximately 30 kDa was observed after gel-filtration of
phaeochromocytoma HSF (lanes b and d), while it was
almost absent in the starting material (lane a) suggesting that
this band is related to proteolysis occurring after SE-HPLC.
To assess further the immunochemical properties of CgA
forms, the relative binding of CgA-I, -II and -III to MAb
Al1 and B4El1 was also examined. These antibodies
recognise epitopes located within residues 68-70 (GAK)
and 81 -90 (GFEDELSEVL) of CgA, respectively, as
mapped using 20 peptides covering most of the CgA
sequence and 12 overlapping peptides encompassing the
CgA(65-96) sequence (A Corti et al., 1996). Thus, these
antibodies could be used to probe the cognate epitopes in
CgA forms. For this purpose, SE-HPLC fractions
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Figure 3 SE-HPLC of a phaeochromocytoma HSF solution (100M,l, 20jugml-1) (a and c) and a serum sample (S4, 100ptl) of a
phaeochromocytoma patient (b and d). Fractions were analysed by CgA M-ELISA (a and b), CgA P-ELISA (c and d).
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corresponding to CgA-I, -II and -III were incubated with
All- and B4EI1I-coated plates. The total bound antigenic
material was detected with a rabbit polyclonal anti-CgA
antibody and quantified using a calibration curve made up
with phaeochromocytoma HSF solutions. As shown in Table
I, the relative immunoreactivity of these fractions to Al1 and
B4E11 was different, suggesting that, in spite of all CgA
forms expressing both epitopes, the accessibility or the
conformation of the cognate epitopes in these forms are
different.
In conclusion, CgA-I, CgA-II and CgA-III, although
appearing to be made up of polypeptides with similar
molecular weight, are characterised by markedly different
hydrodynamic properties and different immunoreactivity.
To investigate whether CgA-I is related to multimeric
complexes, other experiments were undertaken. The results
can be summarised as follows: a series of ELISA experiments
carried out using solid-phase B4E11 in the capturing step and
biotinylated B4E1 in the detection step (homosandwich
ELISA) failed to detect polyvalent aggregated material both
Phaeochr. HSF
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(kDa) a
106 -
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32.5
29.5
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Fraction: SM
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Figure 4 Analysis of SE-HPLC fractions by Western blotting with MAb B4El1. Two aliquots (100pl) of phaeochromocytoma
HSF solutions (20pgml-1 and 1.18mgml-1 in PBS) were gel filtered through a Bio-Sil SEC-250 column as described in 'Materials
and methods' and analysed by M-ELISA. Peak fractions were then subjected to SDS-PAGE and Western blotting with MAb
B4El1. Lane a, phaeochromocytoma HSF (starting material (s.m.) of SE-HPLC); lanes b and c, gel filtration of 20pgml-l
phaeochromocytoma HSF; lanes d, e and f, gel filtration of 1.18mgml-1 phaeochromocytoma HSF. Lanes b and d, CgA-I; lane e,
CgA-II; lanes c and f, CgA-III. This figure also shows the Western blotting of CgA-I of serum S4 chromatography (see Figure 7)
(lane g); CHP-134 cell supernatant (lane h); and CgA purified by affinity chromatography on All-agarose from
phaeochromocytoma HSF (lane i), both used as starting material for SE-HPLC of Figure 2.
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Figure 5 Sandwich ELISA of phaeochromocytoma HSF (a and b), phaeochromocytoma HSF treated with DSS (c), and serum S4
(d and e) using B4E1 1 or All as capturing antibodies and biotin-B4El 1 or biotin-Al 1 as detecting reagents, in both combinations.
The sandwich ELISAs were carried out using the same conditions (buffers and incubation times) as described for M-ELISA (see
Materials and methods) except that for the experiments reported in b and e Tween 20 was omitted from all incubation and washing
buffers. Phaeochromocytoma HSF was treated with DSS as follows: 25 gl of phaeochromocytoma HSF (40 pgml-1) was mixed
with 1.25 ju1 of 25 mm DSS and incubated for 30min at 25°C. Then 3 pl of 1 M ammonium acetate was added to block the cross-
linking reaction.
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in the S4 serum sample and in a phaeochromocytoma HSF
solution (Figure 5a and d), even when detergents were
omitted in the assay incubation and washing buffers (Figure
5b and e). The same results were obtained using MAb All in
a similar homosandwich ELISA, whereas strong signals were
obtained with control heterosandwich ELISA made up with
solid-phase MAb B4E11 and biotinylated All as well as with
solid phase All and biotinylated B4E11 (Figure 5a, b, d and
e). To rule out the possibility that complex dissociation
occurred during assay incubation, phaeochromocytoma HSF
was treated with disuccinimidyl suberate (DSS), a bifunc-
tional reagent widely used to cross-link protein complexes,
and analysed again by the homo- and hetero-sandwich
ELISAs. Also in this case (Figure 5c) no signals were
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detected by the homosandwich ELISAs. Moreover, no bands
corresponding to high molecular weight complexes or
aggregates of CgA were observed by Western blotting
analysis of phaeochromocytoma HSF treated with DSS.
Thus, serum samples as well as tissue extracts contain at
least three forms of CgA that appear to be monomeric
proteins.
Stability of circulating CgA forms
The stability of circulating CgA forms was then investigated.
To this purpose, two phaeochromocytoma plasma samples,
containing mainly CgA-II and a small amount of CgA-I,
were incubated at various temperatures (-20°C, 4°C and
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Table II CgA antigen in phaeochromocytoma SE-HPLC fractions
as measured by ELISA using plates coated with B4El1 and Alla
SE-HPLC CgA (,ug ml-1)
fractionb All B4Ell B4EII/All
CgA-I 28.0+0.7 12.2+0.5 0.43
CgA-II 8.95+0.85 6.55+ 0.15 0.73
CgA-III 4.2+0.2 5.9+0.9 1.40
a The ELISA was carried out essentially as described for P-ELISA,
except thatplates were coated with A 1I or B4E11 and boundCgA was
detected with a rabbit polyclonal anti-phaeochromocytoma serum
(1:5000) followedby agoat anti-rabbit HRPconjugate. bCgAfractions
were obtained by SE-HPLC ofphaeochromocytoma HSF.
37°C) for 72 h and subsequently analysed by SE-HPLC and
P-ELISA. As shown in Figure 6 , a small increase of CgA-I
was observed after incubation at 37°C while a decrease was
observed at 4°C. This indicates that CgA forms may change
as a function of temperature and that CgA-I is unlikely to be
a proteolytic precursor of CgA-II.
Discussion
In this work we have characterised the structure ofcirculating
CgA of phaeochromocytoma patients and compared it with
that of CgA extracted from tumour tissues. The study was
carried out using: (1) various ELISAs set up with monoclonal
and polyclonal antibodies; (2) SE-HPLC, coupled to ELISA
detection of fractions; and (3) Western blotting analysis of
chromatographic fractions with a high affinity anti-CgA
monoclonal antibody (B4Ell).
In accordance with previous findings (O'Connor and
Deftos, 1987), circulating CgA was found to be hetero-
geneous. In particular, CgA was found to circulate in at least
three different antigeneic forms of 600 kDa, 100 kDa and
55 kDa, by SE-HPLC (here called CgA-I, CgA-II and CgA-
III, respectively). The proportion of each form in various
patients was variable. For instance, we found that the serum
of some patients contained only the 600 kDa or the 55 kDa
form, whereas that of other patients contained mixtures of all
forms. These forms were differentially detected by two
immunoassays based on monoclonal and polyclonal anti-
bodies. Moreover, although all these forms express the
epitopes recognised by two monoclonal antibodies (All and
B4E 11), their relative immunoreactivity with these MAbs was
different. Western blotting experiments showed that CgA-I,
CgA-II and CgA-III are resolved in one or two main bands
corresponding to polypeptides of similar molecular weight
(60-70 kDa). Other minor bands likely corresponding to
proteolytic fragments can also be observed. Although
proteolytic processing could contribute to the observed
hydrodynamic behaviour of CgA forms, these results suggest
that the markedly distinct hydrodynamic and immunological
properties of CgA forms are not simply related to proteolytic
fragmentation.
The possibility exists that CgA-I and CgA-II correspond
to multimeric complexes or aggregates. However, we think
that this hypothesis is unlikely for various reasons:
(1) It has been shown previously that CgA aggregates,
thought to be present within the secretory granules, are
characterised by an apparent molecular weight, by gel
filtration, much higher than that observed for CgA-I and
CgA-II (> 1500 kDa) (Yoo and Albanesi, 1990).
(2) The same report showed that, after aggregate dissocia-
tion, CgA still behaves as a large protein close to the
CgA-I of this study.
(3) We were unable to detect multimeric complexes in serum
and tissue samples by several analyses based on
immunological and biochemical methods (see Results).
(4) No CgA binding proteins have been detected in serum
by previous studies (Takiyyuddin et al., 1990).
Although the presence of multimeric complexes in serum
cannot be completely ruled out, we think that other factors
must be taken into account to explain the behaviour of
circulating CgA in gel filtration.
Previous studies have shown that CgA isolated from
chromaffin granules elutes from a column of Sephadex G-200
with an apparent molecular weight close to that of CgA-I,
whereas the same material in the same buffer, shows an
apparent molecular weight of 77 kDa by sedimentation
analysis (Smith and Winkler, 1967). Similar results have
also been reported by other researchers with purified CgA
(Fisher-Colbrie and Schober, 1987). This unusual behaviour
of CgA in gel filtration has been associated with the
conformation of this protein approaching that of a random
coil polypeptide and behaving like a large expanded sphere
with an effective hydrodynamic radius of 77 A.
Thus, the occurrence of a CgA form in serum with an
apparent molecular weight of 600 kDa may be simply
explained by the fact that we used globular proteins to
calibrate the column with presumably smaller hydrodynamic
sizes. However, this would imply that serum also contains
other forms with different conformations and hydrodynamic
sizes like those found in CgA-II and CgA-III, still made up of
polypeptides of 60-70 kDa.
The different relative immunoreactivity of these forms
observed with B4El1 and All, directed against two adjacent
epitopes located within residues 68-70 and 81-90, respec-
tively, could also reflect different epitope conformations in
these proteins.
The finding that serum contains CgA forms with
apparently different molecular sizes may reflect the existence
of similar forms also in tissues. Accordingly, CgA forms with
large (80 A) and small (54 A) Stokes radius have been
identified in the adrenal medulla and in the brain, respectively
(O'Connor and Frigon, 1984).
Evidence for differential proteolytic processing of CgA in
different endocrine cells has been reported (Deftos et al.,
1990, Brandt et al., 1994). Interestingly, in these reports, gel
filtration chromatography studies showed multiple and
distinct immunoreactive species of CgA in different cell
lines. Although the comparison with our serum CgA forms is
difficult, since the molecular weights were not estimated, it is
interesting to note that also in this case forms with
apparently larger than the '25I-CgA standard, used to
calibrate the column, were observed in some cell lines. In
view of the hypothesis that CgA is a multihormone precursor,
the occurrence of forms with different hydrodynamic proper-
ties could have important implications in the regulation of
the proteolytic processing of these proteins in different tissues
or in blood. For instance, it is possible that specific
proteolytic sites are masked or exposed in different forms.
Work aimed at investigating the sensitivity of CgA forms
to proteases and at elucidating the factors that affect their
hydrodynamic behaviours could help in a better under-
standing of the complex structure-function relationships of
chromogranins and of their physiological and pathological
roles in normal subjects and tumour patients.
In conclusion, these results suggest that circulating CgA in
phaeochromocytoma patients consists of at least three
antigenic forms that appear to be made up of polypeptides
with similar molecular weight and different hydrodynamic
properties and immunoreactivity. Since the ratio of CgA
concentrations measured by P- and M-ELISA (P/M ratio) is
dependent on the proportion of these forms over the total,
differential detection of CgA with these assays in a high
number of patients with different tumours may be exploited
to study the diagnostic potential of these forms.
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